Legal possibility of marketing authorization and commercialization of advanced therapy medicinal products in Brazil

Authors

  • Luisa Abreu Obici Garcia Advocacia Geral da União Author
  • Marilia Rodrigues Mendes Takao Agência Nacional de Vigilância Sanitária (Anvisa) Author
  • Renata Miranda Parca Agência Nacional de Vigilância Sanitária (Anvisa) Author
  • João Batista da Silva Junior Agência Nacional de Vigilância Sanitária (Anvisa) Author

DOI:

https://doi.org/10.22239/2317-269X.01075

Keywords:

Advanced Therapies, Stem Cells, Regulation, Marketing Authorization, Constitution

Abstract

In view of the provisions of the Constitution of 1988, of the Federative Republic of Brazil, article 199, paragraph 4, which prohibits any form of marketing of organs, tissues and human substances for transplants, research and treatment, the possibility of commercialization and marketing authorization of human origin products in Brazil has been questioned. With the advent of advanced therapies, legal uncertainty on the subject has reached regulatory issues and permeated scientific and investments concerns over the sector. Such perception based the detailed analysis on the matter by Anvisa´s Federal Attorney’s Office, which was expressed on the Legal Opinion n. 12/2016/PF-Anvisa/PGF/
AGU and exposed in this article. Outline, in this article, the main aspects concerning the legal possibility of marketing authorization and commercialization of advanced therapy medicinal products in Brazil, based on the Legal Opinion n° 12/2016/PF-Anvisa/PGF/AGU. Assessment of the Legal Opinion content and extraction from the document of its main issues. The document concluded for the possibility of a marketing authorization of the advanced therapy medicinal products, considering the principle of human dignity and fundamental rights to life and health, and conditioned it to the elaboration of a strict
regulatory framework.

Downloads

Download data is not yet available.

Author Biographies

  • Luisa Abreu Obici Garcia, Advocacia Geral da União
    Procuradoria Federal junto à Agência Nacional de Vigilância Sanitária – Anvisa. Procuradoria Geral Federal. Advocacia Geral da União / Brasília, Distrito Federal, Brasil
  • Marilia Rodrigues Mendes Takao, Agência Nacional de Vigilância Sanitária (Anvisa)

    Gerência de Sangue, Tecidos, Células e Órgãos. Diretoria de Autorização e Registro Sanitário. Anvisa / Brasília, Distrito Federal, Brasil

  • Renata Miranda Parca, Agência Nacional de Vigilância Sanitária (Anvisa)
    Gerência de Sangue, Tecidos, Células e Órgãos. Diretoria de Autorização e Registro Sanitário. Anvisa / Brasília, Distrito Federal, Brasil
  • João Batista da Silva Junior, Agência Nacional de Vigilância Sanitária (Anvisa)
    Gerência de Sangue, Tecidos, Células e Órgãos. Diretoria de Autorização e Registro Sanitário. Anvisa / Brasília, Distrito Federal, Brasil

Published

2018-02-28

How to Cite

Legal possibility of marketing authorization and commercialization of advanced therapy medicinal products in Brazil. (2018). Health Surveillance under Debate: Society, Science & Technology , 6(1), 6-14. https://doi.org/10.22239/2317-269X.01075

Similar Articles

1-10 of 161

You may also start an advanced similarity search for this article.